Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparative Effectiveness of Therapies for Children With Autism Spectrum Disorders

Slide: 33 of 36

Note Regarding Possible Harms

Adverse events were not reported for most interventions. They were reported, however, for the antipsychotics risperidone and aripiprazole (see clinical bottom line), serotonin-reuptake inhibitors (decreased sleep, increased energy), guanfacine, and stimulants. Other than for risperidone and aripiprazole, there was not enough evidence to permit conclusions to be drawn about the severity and frequency of potential adverse events associated with any of the interventions. According to the U.S. Food and Drug Administration, there are serious safety issues associated with chelation products. Even when used under medical supervision, these products may cause serious harm, including dehydration, kidney failure, and death.